CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Vaccine Candidate

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...
Scientific American

Scientists Explain How mRNA COVID Vaccines May Rarely Cause Myocarditis

A new study identifies a mechanism for how COVID vaccines may, in infrequent cases, drive heart inflammation, a condition ...
News-Medical.Net on MSN

Opposing protein forces fine tune mRNA stability in human cells

A newly revealed molecular tug-of-war may have implications for better understanding how a multitude of diseases and ...

Scientists develop a smarter mRNA therapy that knows which cells to target

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...

It's being used to fight cancer, flu and the next pandemic, but what exactly is mRNA?

Aside from maybe high school biology classes, the first time many people heard of mRNA was during the pandemic because of the ...

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s mNEXSPIKE (COVID-19 Vaccine, mRNA)

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

Study unveils improved mRNA cancer vaccine targeting

No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating ...
Donga Science

An mRNA cocktail rejuvenates T cells and boosts immunity in aged mice

A therapy based on messenger RNA (mRNA), a genetic material actively studied for vaccines and other applications, has turned ...

French Study on mRNA COVID-19 Vaccines Finds a Drop in Severe COVID—and No Increase in Deaths

Vaccinated adults had a 74 percent lower risk of dying from COVID-19—and a 25 percent lower risk of dying, period.

Moderna, Inc.: CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic threat ...
News-Medical.Net on MSN

First-of-its-kind mRNA system switches on therapeutic genes inside targeted cells

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells-an advance ...
News Medical on MSN

New Binghamton University research shows better way to target mRNA cancer vaccines

No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating ...